AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie is highlighted as continuing growth via a major $10.9B acquisition of Apogee Therapeutics, with FY2025 revenue near $61.2B (+8.7%) and free cash flow around $17.8B. Eli Lilly is framed as the stronger growth story, with FY2025 revenue near $65.2B (+45%) and GLP-1 drugs (Mounjaro/Zepbound) driving about 56% of sales; it is projected to grow revenue up to ~30% in 2026 to ~$85.2B and net income to about ~$31B. Offsetting risks include AbbVie’s patent/biosimilar pressure and IRA-driven price reductions, while Lilly faces high concentration in a few therapies and competitive/manufacturing supply-chain risks. Valuation also skews higher for Lilly (Forward P/E 32.4x vs 18.4x), but the article ultimately favors Lilly for long-term investors.

Analysis

The market is already paying for Lilly as a secular growth story, so the next leg is less about the size of the obesity market and more about execution quality: manufacturing uptime, payer access, and whether newer assets prove incremental rather than just narrative support. That makes the stock vulnerable to any hint that demand is outpacing sell-through or that net pricing is being pressured by rebates; in a high-multiple name, small operating misses can drive disproportionate multiple compression over the next 1-3 quarters.

AbbVie reads differently: it is a cash-flow machine trying to buy durability before the next patent wall becomes a valuation event. The M&A path can support sentiment, but the bigger second-order effect is that diversified pharma with a broad formulary footprint should retain negotiating leverage as policymakers and payers push harder on pricing; that favors ABBV over narrower biotech names and makes the equity more resilient than its leverage optics suggest. If the pipeline can re-rate even one or two late-stage programs, the current discount to Lilly is not obviously justified on a 6-18 month view.

Contrarian take: consensus may be underestimating how crowded the “GLP-1 winner” trade has become. Lilly’s franchise is excellent, but the stock likely needs continued upward revisions to avoid becoming a duration asset with pharma-specific supply and reimbursement risk. ABBV is the better setup if the market shifts from growth purity back toward free cash flow and downside protection. The thesis breaks if Lilly’s 2026 growth guide is revised down or if AbbVie’s core immunology growth slows materially after integration spending ramps.

Key Decisions for Investors

• Long LLY on 5-10% pullbacks over the next 1-2 months; use any commentary on supply, net pricing, or payer friction as the key falsifier. Reward is continued estimate revisions, but position size should reflect elevated multiple risk.
• Pair trade: long ABBV / short XBI for a 3-6 month horizon. This expresses preference for cash-flow durability and broad-pipeline optionality versus crowded biotech beta; thesis weakens if ABBV core growth slows or pipeline news disappoints.
• If already long LLY, buy downside protection into earnings or regulatory milestones rather than chasing upside calls; the stock is more exposed to a guidance miss than the market implies.
• Watch APGE as a potential optionality screen, not a standalone long: upside only if AbbVie proves it can convert acquisition spending into visible 2027+ growth.